Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend

OBJECTIVE: Fracture risk increases with age, but few studies focus on persons ≥80 years. In the ACTIVE trial, treatment with abaloparatide for 18 months reduced osteoporotic fracture risk and increased bone mineral density. These effects were maintained with 24 months alendronate treatment in ACTIVE...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Menopause
Huvudupphovsmän: Greenspan, Susan L., Fitzpatrick, Lorraine A., Mitlak, Bruce, Wang, Yamei, Harvey, Nicholas C., Deal, Chad, Cosman, Felicia, McClung, Michael
Materialtyp: Artigo
Språk:Inglês
Publicerad: Lippincott Williams & Wilkins 2020
Ämnen:
Original Studies
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7515468/
https://ncbi.nlm.nih.gov/pubmed/32665529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/GME.0000000000001593
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk